Back to News
Market Impact: 0.2
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Source: businesswire.com
Healthcare & Biotech
AbCellera announced it will present Phase 2 data for ABCL635 at the IMS World Congress on Menopause 2026. The release does not disclose efficacy, safety, or financial data, limiting the immediate valuation impact until the trial results are presented.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
ABCL0.35
More News
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Japan has a problematic age gap: 100,000-plus residents are over 100 and the pension system is buckling
- The MLB and its Dominican pipeline is selling false promises and shady contracts to children as young as 11
- Arrowhead Pharmaceuticals at H.C. Wainwright: launch and pipeline widen
- A healthcare provider is set up for a big move higher, according to the charts
- Scientists challenge US NIH grant screening as unconstitutional